GlassScriptPhysician profile
Abdul Q Haseeb
NPI 1962467605
$1,000.37
in general payments reported to CMS, 2019-2025
16 companies · $149 in 2025
The $149 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $98.13 · 2021: $74.08 · 2022: $221 · 2023: $90.19 · 2024: $197 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $436.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $189.34 | 2021-2022 | |
| Glaxosmithkline, LLC. | $127.33 | 2019-2024 | Rotarix, Pediarix, Bexsero |
| Pfizer INC. | $115.97 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $114.44 | 2022-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Aurinia Pharma U.S., INC. | $71.42 | 2025 | Lupkynis |
| Supernus Pharmaceuticals, INC. | $61.39 | 2021-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $46.60 | 2024 | |
| Sanofi Pasteur INC. | $44.66 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $43.83 | 2019 | |
| Ardelyx, INC. | $42.60 | 2024 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $39.97 | 2020 | |
| Genzyme Corporation | $32.18 | 2025 | |
| Mirum Pharmaceuticals, INC. | $21.22 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.49 | 2019 | |
| Verrica Pharmaceuticals INC. | $16.39 | 2023 | Ycanth |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $13.54 | 2023 | Odactra, Grastek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Haseeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.